Final Approval of $264 Million Settlement with Mylan Defendants Granted in EpiPen Class Action, Resulting in Total Recovery of $609 Million for the Class
July 11, 2022 – Judge Daniel D. Crabtree has granted final approval to the $264 million settlement between Plaintiffs and the Mylan Defendants in In re: EpiPen Marketing, Sales Practices and Antitrust Litigation, MDL No. 2785, finding the settlement to …